Strategies for Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Selection and Sequencing of Newer and Emerging Treatment Options

FACULTY

Mehdi Hamadani, MD
Professor of Medicine
Medical College of Winconsin

Manali Kamdar, MD
Associate Professor of Medicine
University of Colorado Cancer Center

Brian Link, MD
Professor of Internal Medicine- Hematology, Oncology and Blood & Marrow Transplantation
University of Iowa Medicine

Kami J. Maddocks, MD
Professor of Clinical Internal Medicine and Director of Lymphoma
James Cancer Hospital, Ohio State University

Ari M. Melnick, MD
Gebroe Family Professor of Hematology/Oncology; Chair, Hematologic Malignancies Program
Weill Cornell Medical College

Lia Palomba, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center

Adrienne Phillips, MD
Medical Oncologist
Weill Cornell Medicine

Jia Ruan, MD
Professor of Clinical Medicine
Weill Cornell Medicine

Sarah Rutherford, MD
Assistant Professor of Medicine
Weill Cornell Medicine

Koen van Besien, MD
Directpr of Stem Cell Transplant program, Professor of Medicine
Weill Cornell Medicine
 

PROVIDER STATEMENT

Provided by North American Center for Continuing Medical Education, LLC (NACCME), an HMP Global Company.

For questions regarding this educational activity, please call 609-371-1137 or email info@naccme.com.

INTENDED LEARNERS

This activity is designed for a national and international audience of hematologists; hematologic, medical, radiation, and surgical oncologists; hematopathologists; and other health care providers, including pathologists, oncology and health-system pharmacists, oncology nurses, nurse practitioners, physician assistants, residents/fellows, and other clinicians involved and/or interested in the therapeutic management of patients with hematologic malignancies.

LEARNING OBJECTIVES

After participating in this activity, learners should be better able to:

• Summarize the latest clinical data concerning newer and emerging therapies for the treatment of DLBCL and FL
• Apply current guidelines for optimal treatment selection and sequencing to individualize disease management in DLBCL and FL
• Evaluate the toxicity profiles of diverse agents for DLBCL and FL and corresponding evidence-based management tactics

CLAIMING CREDIT

To be eligible for credit, participants must complete the online activity and the evaluation. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.

Release Date: November 30, 2021
Expiration Date: November 30, 2022
Estimated Time to Complete: 2.0 hours

There is no fee associated with this activity.

COMMERCIAL SUPPORT

The following companies have provided educational grants in support of this activity: Genmab US, Inc

CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

PHYSICIANS

NACCME designates this internet enduring activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES

This continuing nursing education internet live/enduring activity awards 2.0 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 2.0 contact hours. 

NURSE PRACTITIONERS

American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit^TM from organizations accredited by the ACCME.

PHARMACISTS

This internet enduring, knowledge-based activity (Universal Activity Number: JA0006201-0000-21-216-H01-P) has been approved for a maximum of 2.0 contact hours (.2 CEUs).

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in the CPE Monitor system. Following ACPE Policy, NACCME must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity. NACCME is not able to report your claimed credit after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.

PHYSICIAN ASSISTANTS

NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 2.0 AAPA Category 1 credits. PAs should only claim credit commensurate with the extent of their participation.

USE OF PROPRIETARY NAMES

This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.

UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.

DISCLAIMERS

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

NACCME, LLC is an independent provider of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

In accordance with our disclosure policies, NACCME is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real conflicts of interest between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME.

Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:

1. Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
2. Any investigational, off-label, or non-FDA approved content or discussion

NACCME has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.

Education has been independently peer-reviewed to validate content, mitigate identified conflicts of interest, and ensure:

1. All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
2. All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
3. Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.

FACULTY

The faculty has reported the following:

Mehdi Hamadani: Advisory Board-ADC Therapeutics, Morphosys, Omeros, Pharmacyclics; Consultant-ADC Therapeutics, Verastem; Speakers Bureau-AstraZeneca, BeiGene, Sanofi

Manali Kamdar: Consultant - AbbVie, Acerta/AstraZeneca, Bristol Myers Squibb; Grant/Research Support - Genentech/Roche, TG Therapeutics; Speakers Bureau - Seattle Genetics; Other - Celgene

PLANNING COMMITTEE

Samantha Conforti, Kelly Jackson, Paul O'Neil, Amrita Kabi, and Greaton Sellers from NACCME and Imedex have disclosed no relevant financial relationship with any ineligible company (commercial interest).

ADA STATEMENT

North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.

PRIVACY POLICY

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2021 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.

GRIEVANCE POLICY

Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by NACCME, LLC may contact Samantha Conforti, Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at sconforti@naccme.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. Ms. Conforti will review the grievance and respond within 30 days of receiving the complaint. If the participant is unsatisfied with the response, an appeal to the Associate Director, Greaton Sellers,  Accreditation and Compliance, can be requested for a second level of review. Mr. Sellers can be contacted via phone at 609-371-1137, by email at gsellers@naccme.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520.